Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions

Small. 2015 Aug;11(31):3755-61. doi: 10.1002/smll.201500324. Epub 2015 Apr 28.

Abstract

A strategy for enhancing the treatment efficacy of nanomedicines within the central region of solid tumors is developed by combining nanomedicines and free small-molecule vascular disrupting agents (VDAs). The nanomedicines (cis-diamminedichloroplatinum-loaded nanoparticles) primarily target cells at the tumor periphery whereas the free small-molecule VDA (combretastatin A4 disodium phosphate) efficiently kills the cancer cells within the central regions of the tumor.

Keywords: cisplatin; coadministration; nanomedicines; tumors; vascular disrupting agents.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acoustics
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / chemistry*
  • Animals
  • Antineoplastic Agents / chemistry
  • Cell Line, Tumor
  • Cisplatin / chemistry
  • Drug Therapy, Combination
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Nanomedicine / methods*
  • Nanoparticles / administration & dosage
  • Nanoparticles / chemistry*
  • Neoplasms / drug therapy*
  • Stilbenes / chemistry

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Stilbenes
  • fosbretabulin
  • Cisplatin